Castration-resistant Clinical Trials

1 recruiting

Castration-resistant Trials at a Glance

137 actively recruiting trials for castration-resistant are listed on ClinicalTrialsFinder across 6 cities in 49 countries. The largest study group is Phase 2 with 67 trials, with the heaviest enrollment activity in New York, Los Angeles, and San Francisco. Lead sponsors running castration-resistant studies include Novartis Pharmaceuticals, University of Utah, and AstraZeneca.

Browse castration-resistant trials by phase

Treatments under study

About Castration-resistant Clinical Trials

Looking for clinical trials for Castration-resistant? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Castration-resistant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Castration-resistant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 137 trials

Recruiting
Phase 1

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Breast CancerCervical CancerColon Cancer+4 more
Orano Med LLC48 enrolled4 locationsNCT05283330
Recruiting
Phase 2

SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University66 enrolled3 locationsNCT07451795
Recruiting
Phase 1Phase 2

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Stage IVB Prostate Cancer AJCC v8Metastatic Malignant Neoplasm in the BoneMetastatic Castration-Resistant Prostate Carcinoma+1 more
National Cancer Institute (NCI)90 enrolled32 locationsNCT04071236
Recruiting
Phase 1

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Advanced Metastatic Castration-resistant Prostate CancerProstate Specific Membrane Antigen (PSMA) Expression
Bayer198 enrolled35 locationsNCT06217822
Recruiting
Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled324 locationsNCT06136650
Recruiting

PRostate Olaparib Real World Evidence Study

Metastatic Castration-resistant Prostate Cancer
AstraZeneca300 enrolled65 locationsNCT06031805
Recruiting
Phase 2

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium126 enrolled2 locationsNCT06844383
Recruiting
Phase 1Phase 2

Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

Prostate CancerNeoplasmsNeoplasms by Site+7 more
Pathos AI, Inc.252 enrolled18 locationsNCT06785636
Recruiting
Phase 1

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Roswell Park Cancer Institute14 enrolled1 locationNCT06305598
Recruiting
Phase 3

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled125 locationsNCT07213674
Recruiting
Phase 2

Bipolar Androgen Therapy + Carboplatin in mCRPC

Homologous Recombination DeficiencyCastration-resistant Prostate Cancer
St Vincent's Hospital, Sydney30 enrolled1 locationNCT03522064
Recruiting

Intestinal Akkermansia Muciniphila in Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Assistance Publique - Hôpitaux de Paris52 enrolled1 locationNCT06242509
Recruiting
Phase 2

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Biochemically Recurrent Prostate CarcinomaRecurrent Castration-Sensitive Prostate CarcinomaRecurrent Prostate Cancer+1 more
Mayo Clinic532 enrolled3 locationsNCT06378866
Recruiting
Phase 1Phase 2

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

MetastasisCastration-Resistant Prostatic Cancer
Merck Sharp & Dohme LLC360 enrolled75 locationsNCT06863272
Recruiting
Phase 1

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Urothelial CarcinomaRenal Cell CarcinomaCastration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC60 enrolled4 locationsNCT06966024
Recruiting
Phase 1

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Prostate CancerMetastatic Castration-resistant Prostate CancerCastration-resistant Prostate Cancer
Janux Therapeutics43 enrolled1 locationNCT07545811
Recruiting
Phase 1

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Stage IVB Prostate Cancer AJCC v8Metastatic Castration-Resistant Prostate Adenocarcinoma
City of Hope Medical Center30 enrolled1 locationNCT07219147
Recruiting
Phase 2

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Prostate CancerProstate CarcinomaMetastatic Castration-resistant Prostate Cancer+1 more
University of California, San Francisco48 enrolled1 locationNCT05766371
Recruiting
Phase 1Phase 2

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC220 enrolled77 locationsNCT06353386
Recruiting
Phase 2

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446